UNSPSC 51101666: Moxnidazole

This classification denotes an antiprotozoal agent with the molecular formula C13H18N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9J21260BCQ, chemically known as 2-oxazolidinone, 3-(((1-methyl-5-nitro-1h-imidazol-2-yl)methylene)amino)-5-(4-morpholinylmethyl)- but generally known as moxnidazole, which bears US NIH Compound Identifier 9571039. European Medicines Agency schedules Moxnidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09091MIG.

UNSPSC 51101666 Moxnidazole is a Commodity code nominally covering a specific pharmaceutical ingredient, but recent state and local solicitations show little activity directly aligned with moxnidazole procurement itself. Instead, the code's recent opportunities center on broader pharmaceutical and medical supply acquisitions—generic multi-source pharmaceuticals, naloxone products, and first-aid supplies for emergency response and health initiatives. State and local buying under this code reflects a mix of county health departments, state health commissions, municipal fire departments, and cooperative purchasing alliances sourcing emergency pharmaceuticals, OTC products, and medical consumables. The work involves competitive bidding processes with wholesale distribution requirements, FDA compliance certification, cGMP adherence, and product-availability guarantees tied to specific National Drug Codes and shelf-life minimums.

Geographic activity spans multiple regions, with recent opportunities posted by Seminole County, Florida; the Texas Health and Human Services Commission; the City of Tampa, Florida; and the Minnesota Multistate Cooperative Purchasing Alliance (serving Minnesota and Oregon members). Representative recent opportunities include the Minnesota MMCAP's RFP (issued January 20, 2026, due March 26, 2026) establishing multi-year contracts for generic pharmaceuticals and OTC products through authorized wholesalers with pricing weighted 75 percent on competitiveness; Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023) with quarterly deliveries to the county's community health building; and the City of Tampa's IFB for 169 line items of medical and first-aid supplies for the Fire Department Rescue Division (due March 13, 2026) designated as a sheltered market opportunity for certified Small Local Business Enterprises with a $700,000 estimated contract amount. The Texas HHS Commission's RFI (posted April 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription programs, signaling exploratory-stage procurement development. The code shows modest, dispersed activity across emergency medical and health-initiative procurement rather than concentrated moxnidazole sourcing.